These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22551309)

  • 1. Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma.
    Kast RE; Lefranc F; Karpel-Massler G; Halatsch ME
    Br J Neurosurg; 2012 Dec; 26(6):813-7. PubMed ID: 22551309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale of targeting neutrophils with dapsone during glioblastoma treatment.
    Kast RE; Scheuerle A; Wirtz CR; Karpel-Massler G; Halatsch ME
    Anticancer Agents Med Chem; 2011 Oct; 11(8):756-61. PubMed ID: 21707494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapsone as treatment adjunct in ARDS.
    Kast RE
    Exp Lung Res; 2020; 46(5):157-161. PubMed ID: 32286085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.
    Kast RE
    Med Sci (Basel); 2021 Feb; 9(1):. PubMed ID: 33669324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapsone in dermatology and beyond.
    Wozel G; Blasum C
    Arch Dermatol Res; 2014 Mar; 306(2):103-24. PubMed ID: 24310318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction.
    Debol SM; Herron MJ; Nelson RD
    J Leukoc Biol; 1997 Dec; 62(6):827-36. PubMed ID: 9400824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner.
    Suda T; Suzuki Y; Matsui T; Inoue T; Niide O; Yoshimaru T; Suzuki H; Ra C; Ochiai T
    Br J Dermatol; 2005 May; 152(5):887-95. PubMed ID: 15888142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dapsone in skin diseases].
    Zalewska A; Napieralska-Krzysiek E
    Pol Merkur Lekarski; 2003 Nov; 15(89):484-6. PubMed ID: 14969150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones.
    Harvath L; Yancey KB; Katz SI
    J Immunol; 1986 Aug; 137(4):1305-11. PubMed ID: 3016092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance.
    Coleman MD
    Br J Dermatol; 1993 Nov; 129(5):507-13. PubMed ID: 8251346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.
    Kast RE
    Springerplus; 2015; 4():638. PubMed ID: 26543772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapsone and sulfones in dermatology: overview and update.
    Zhu YI; Stiller MJ
    J Am Acad Dermatol; 2001 Sep; 45(3):420-34. PubMed ID: 11511841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures.
    Vezzani A; Maroso M; Balosso S; Sanchez MA; Bartfai T
    Brain Behav Immun; 2011 Oct; 25(7):1281-9. PubMed ID: 21473909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum.
    Seneschal J; Guillet S; Ezzedine K; Taïeb A; Milpied B
    Dermatology; 2012; 224(2):115-9. PubMed ID: 22508198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease.
    Lipsker D; Perrigouard C; Foubert A; Cribier B
    Dermatology; 2010; 220(3):264-7. PubMed ID: 20197651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action of dapsone in chronic inflammatory dermatoses. I: Modification of the functions of polymorphonuclear leukocytes].
    Wozel G
    Dermatol Monatsschr; 1987; 173(10):569-76. PubMed ID: 3322889
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells.
    Uetrecht J; Zahid N; Shear NH; Biggar WD
    J Pharmacol Exp Ther; 1988 Apr; 245(1):274-9. PubMed ID: 3129552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.
    Karpel-Massler G; Kast RE; Siegelin MD; Dwucet A; Schneider E; Westhoff MA; Wirtz CR; Chen XY; Halatsch ME; Bolm C
    Neurochem Res; 2017 Dec; 42(12):3382-3389. PubMed ID: 28852934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the anti-inflammatory effects of topical dapsone for management of acne.
    Kircik LH
    J Drugs Dermatol; 2010 Jun; 9(6):667-71. PubMed ID: 20645528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.